These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8491059)

  • 1. Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.
    Fabre D; Bressolle F; Goméni R; Bouvet O; Dubois A; Raffanel C; Gris JC; Galtier M
    Clin Pharmacokinet; 1993 Apr; 24(4):333-43. PubMed ID: 8491059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian estimation of doxorubicin pharmacokinetic parameters.
    Bressolle F; Ray P; Jacquet JM; Brès J; Galtier M; Donadio D; Jourdan J; Rossi JF
    Cancer Chemother Pharmacol; 1991; 29(1):53-60. PubMed ID: 1742849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
    Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
    Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
    Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
    Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.
    St Peter JV; Awni WM
    Clin Pharmacokinet; 1991 Jan; 20(1):50-65. PubMed ID: 2029802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of acute biliary pancreatitis on liver metabolism of phenazone].
    Hartleb M; Nowak A; Nowakowska-Duława E; Mańczyk I; Becker A; Kacperek T
    Pol Arch Med Wewn; 1990 Mar; 83(3):104-10. PubMed ID: 2216933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic parameters of antipyrine in dog after hepatectomy.
    Galtier M; Briand D; Pinguet F; Gomeni R; Fabre D; Bressolle F
    Biopharm Drug Dispos; 1995 Nov; 16(8):669-84. PubMed ID: 8573686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microsomal oxidative metabolism in the liver of rats treated with vinorelbine: evaluation through antipyrine elimination].
    Montenegro-Alvarez P; González-Alfonso M; Cantarino-Aragón MH; Gutiérrez-Ortega C; Guijarro-Escribano FJ
    Gastroenterol Hepatol; 2006 Apr; 29(4):224-30. PubMed ID: 16584692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
    Wiela A; Orzechowska-Juzwenko K; Kotlarek-Haus S; Plamieniak B; Wolowiec D
    Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):562-5. PubMed ID: 3243660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
    Mahmoud M; Abdel-Kader R; Hassanein M; Saleh S; Botros S
    Eur J Pharmacol; 2007 Aug; 569(3):222-7. PubMed ID: 17628532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.
    Groen K; Horan MA; Roberts NA; Gulati RS; Miljkovic B; Jansen EJ; Paramsothy V; Breimer DD; van Bezooijen CF
    Clin Pharmacokinet; 1993 Aug; 25(2):136-44. PubMed ID: 8403737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of ovariectomy in women on metabolism of phenazone].
    Konieczny M
    Ginekol Pol; 1996 Sep; 67(9):451-6. PubMed ID: 9289465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
    Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
    Br Med J; 1977 May; 1(6073):1384-7. PubMed ID: 861646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
    Janus K; Baranow-Baranowski S; Jakubowska D
    Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenazone metabolism in patients with liver disease.
    Andreasen PB; Greisen G
    Eur J Clin Invest; 1976 Jan; 6(1):21-6. PubMed ID: 1253807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of disorders of thyroid function on phenazone pharmacokinetics].
    Bolanowski M; Orzechowska-Juzwenko K; Gruszka S; Szymczak J
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):136-9. PubMed ID: 2216953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of the antipyrine test for studying microsomal drug oxidation].
    Viktorov AP; Rybak AT
    Farmakol Toksikol; 1990; 53(1):74-7. PubMed ID: 2184052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of total parenteral nutrition on hepatic drug oxidation.
    Burgess P; Hall RI; Bateman DN; Johnston ID
    JPEN J Parenter Enteral Nutr; 1987; 11(6):540-3. PubMed ID: 3123723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.